This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): nepafenac 0.1% ophthalmic suspension TID
Description: NEVANAC suspension is a novel pro-drug that rapidly penetrates ocular tissues and is converted intraocularly into amfenac, a potentnon-steroidal anti-inflammatory drug (NSAID). Because of its pro-drug structure, NEVANAC suspension penetrates the cornea rapidly,reaching target sites while minimizing surface accumulation and potentially reducing the risk of ocular surface complications.
Deal Structure: Nevanac was originally developed by Alcon.
In January 2010, Novartis and Nestl initiated completion of the 2008 agreement, whereby Novartis is exercising its call option to acquire Nestl's remaining 52% Alcon stake for USD 28.1 billion, or USD 180 per share. In combination with the 25% stake initially purchased in April 2008, this acquisition gives Novartis 77% ownership of Alcon. To attain a 100% ownership of Alcon, Novartis proposed to acquire the remaining 23% held by minority shareholders, at a fixed exchange ratio of 2.80 Novartis shares for each remaining Alcon share. In August 2010, Novartis announced that it completed its purchase of Alcon stock from Nestle resulting in 77% ownership of Alcon.
In December 2010, Novartis announced that it entered into a definitive agreement to merge Alcon into Novartis for a combination of cash and Novartis shares. In April 2011, Novartis announced that it completed the merger of Alcon into Novartis.
Pink Sheet Alcon Nevanac approval
Additional information available to subscribers only: